Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biogen, Acorda To Develop Fampridine

by Lisa M. Jarvis
July 13, 2009 | A version of this story appeared in Volume 87, Issue 28

Biogen Idec is expanding its portfolio of multiple sclerosis drugs, which already includes the marketed products Avonex and Tysabri, as well as several small molecules in late-stage development, through a deal with Acorda Therapeutics. Biogen will fork over up to $400 million in payments to jointly develop Acorda's MS drug Fampridine-SR in markets outside the U.S. Fampridine-SR is an oral drug that aims to improve the insulation of frayed nerve fibers in the brain by blocking potassium-ion channels. In Phase III trials, a shorter-acting version of the drug has improved walking ability in people with MS. Elan, Acorda's partner for Fampridine-SR in the U.S., will get 7% of any payments Acorda receives from Biogen.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.